The World Factbook CIA Home CIA Home About CIA Careers Offices of CIA News & Information Library TEEN?s Page Contact CIA CENTRAL INTELLIGENCE AGENCY


This page was last updated on 31 May, 2007

Map of Algeria

Metastatic gastric adenocarcinoma icd 10 code:
Definition Field Listing
20526 8520527 20550 20551 20552 20553 20555 20555 20600 20605 20610 20612 20615 27096 64479 64480 64483 64484 64490 64491 64492 64493. INJECTION, IMMUNE GLOBULIN, (GAMUNEX-C/GAMMAKED), NON-LYOPHILIZED (E.G., LIQUID), 500 MG. * Code based upon total mg applied on date of service; even if applied over multiple sites. o For example, if the quantity administered is 300mg and the description of the drug code is 10 mg, the units billed should be thirty (30). Anthem Central Region bundles J2001 as redundant/mutually exclusive to 20526-20527, 20550-20555, 20600-20615, 27096, 64479, 64480-64484, 64490-64495. Based on the National Correct Coding Initiative Edits, code J2001 is listed as a component code to codes 20526-20527, 20550-20553, 20600- 20615, 27096, 64479, 64483, 64490-64495. Therefore, if J2001 is submitted with 20526-20527, 20550- 20555, 20600-20615, 27096, 64479, 64480-64484, 64490-64495—only 20526-20527, 20550-20555, 20600-20615, 27096, 64479, 64480-64484, 64490-64495 reimburses. Bleomycin sulfate, 15 units (Blenoxane) (J9040) Warts B07.0, B07.8, B07.9 2. UN Unit If a drug is supplied in a vial in powder form, and must be reconstituted before administration, bill each vial (unit/each) used. INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G., LIQUID), 500 MG. read the medical record and determine which elements of the encounter require codes. Cyclophosphamide (Cytoxan) 100 mg (J9070) See section F for non-oncological uses. 6. 2. The units billed must correspond with the smallest dose (vial) available for purchase from the manufacturer(s) that could provide the appropriate dose for the patient code is 10 mg, the units billed should be thirty (30). Character X is used as a placeholder in certain 6- and 7-character codes. The NDC will not be enforced for G codes and P codes. What drug codes require the NDC to be submitted on professional claims effective Jan. 1, 2017? 3-character category, 4th 5th 6th characters for etiology, anatomic site, severity, 7th character for additional information. Mandatory after 3rd character, except E codes, where decimal point is after 4th character. If you use 0.25 cc 1.5 mg/6 mg = 1 Unit If you use 0.5 cc 3 mg/6 mg = 1 Unit If you use 0.75 cc 4.5 mg/6 mg = 1 Unit If you use 1.0 cc 6 mg/6 mg = 2 Units. The following serves to clarify billing guidelines and provide examples of proper billing with a singledose vial and discarded drug billing:. F2 International unit International units will mainly be used when billing for Factor VIII-Antihemophilic Factors. Medicare claim address, phone numbers, payor id - revised list. 3-digit category, 4th and 5th digits for etiology, anatomic site, manifestation. uses drugs to kill cancer cells. It is also used to treat widespread metastases that cannot be surgically removed. code to identify: alcohol abuse and dependence ( ICD-10-CM Diagnosis Code F10. C16.5 Malignant neoplasm of lesser curvature of stomach, unspecified. C16.6 Malignant neoplasm of greater curvature of stomach, unspecified. malignant carcinoid tumor of the stomach ( ICD-10-CM Diagnosis Code C7A.092. C16.8 Malignant neoplasm of overlapping sites of stomach. Type 2 Excludes Help A type 2 excludes note represents "not included here". A type 2 excludes note indicates that the condition excluded is not part of the condition it is excluded from but a patient may have both conditions at the same time. When a type 2 excludes note appears under a code it is acceptable to use both the code ( C16 ) and the excluded code together. Use Additional Help Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation. In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere." Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code. "In diseases classified elsewhere" codes are never permitted to be used as first listed or principle diagnosis codes. They must be used in conjunction with an underlying condition code and they must be listed following the underlying condition. A primary or metastatic malignant neoplasm involving the stomach. ( D41 ) Neoplasm of uncertain or unknown behaviour of urinary organs. ( D16.0 ) Scapula and long bones of upper limb. ( D20 ) Benign neoplasm of soft tissue of retroperitoneum and peritoneum. ( D47.9 ) Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified. ( C47 ) Malignant neoplasm of peripheral nerves and autonomic nervous system. ( C57 ) Malignant neoplasms of other and unspecified female and genital organs. Produced by the World Health Organization, it is used in several countries around the world. Some have gone on to develop their own national enhancements, building off the international version of the classification. ( D35 ) Benign neoplasm of other and unspecified endocrine glands. ( D33 ) Benign neoplasm of brain and other parts of central nervous system. ( C39 ) Malignant neoplasms of other and ill-defined sites in respiratory system and intrathoracic organs. (C97) Malignant neoplasms of independent (primary) multiple sites. Archived: The guideline recommended care options are no longer current or valid. This guideline should be used for historical purposes only. Overview of tumors, cancer and oncology ( C00–D48, 140–239 ). ( C14 ) Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx. (C81–C96) Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue. Tumours of bone and cartilage ( ICD-O 9180–9269) ( C40–C41/D16, 170/213 ). ( C26 ) Malignant neoplasms of other and ill-defined Digestive Organs. Risk factors ( Alcohol, Hereditary breast—ovarian cancer syndrome, BRCA mutation ). (C97) Malignant neoplasms of independent (primary) multiple sites. ( D14.0 ) Middle ear, nasal cavity and accessory sinuses. ( C85 ) Other and unspecified types of non-Hodgkin's lymphoma.